Anticoagulant selection for patients with VTE—Evidence from a systematic literature review of network meta-analyses
Open Access
- 21 March 2019
- journal article
- review article
- Published by Elsevier BV in Pharmacological Research
- Vol. 143, 166-177
- https://doi.org/10.1016/j.phrs.2019.03.017
Abstract
No abstract availableKeywords
Funding Information
- Pfizer, Inc.
- Bristol-Myers Squibb Company
This publication has 41 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismThe New England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological studyBMJ, 2011
- Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapyJournal of Thrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2009
- A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging StudyBlood, 2008
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging studyJournal of Thrombosis and Haemostasis, 2008
- Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE RegistryThrombosis and Haemostasis, 2008